491 results about "Heart failure" patented technology

The invention relates to the technical field of active peptides, in particular to a myocardial active peptide capable of relieving heart failure and protecting heart and a preparation method thereof. The method takes pig hearts as raw materials, and sequentially comprises the following steps: pretreating the pig hearts, adding water, and homogenizing; adding alkaline protease to carry out first constant-temperature enzymolysis; adding neutral protease and flavourzyme to carry out second constant-temperature enzymolysis; then lipase is added for third-time constant-temperature enzymolysis, and enzyme deactivation and cooling are carried out; and finally, adding activated carbon into the enzymatic hydrolysate, filtering with diatomite, and spray-drying to obtain the myocardial active peptide. According to the method, the yield and the purity of the active peptide are remarkably improved through a synergistic process of three-step enzymolysis and activated carbon purification, the obtained product is rich in small molecule peptide with a definite heart protection function, and a new way is provided for high-value utilization of pig heart resources and development of functional products for preventing and treating heart failure.

The invention discloses an intelligent rehabilitation monitoring method and device for a heart failure patient, and relates to the technical field of rehabilitation data processing.The method comprises the steps that on the basis of multiple collection time scales, monitoring item time sequence data sets are obtained, and the monitoring item time sequence data sets comprise the time sequence data set, corresponding to the multiple collection time scales, of each monitoring item; health feature value extraction is carried out on the time sequence data set of the monitoring items, and feature value sequences corresponding to different collection time scales are generated; constructing a multi-time-scale multivariate sequential sequence, and quantifying a physiological system elasticity coefficient value of the heart failure patient by using a preset event elasticity extraction mechanism; and inputting the multi-time-scale multivariate sequential sequence and the elastic coefficient value as monitoring features into a heart failure rehabilitation trajectory prediction model, outputting a health index sequence in a future intervention window, and performing elastic loss critical point identification as an early intervention point. Therefore, the accuracy and foresight of monitoring the rehabilitation health trend of the heart failure patient are improved.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

The invention relates to the technical field of heart failure auxiliary diagnosis and treatment, in particular to a heart failure auxiliary diagnosis and treatment knowledge distillation method and system.The knowledge distillation method comprises the steps that an age-crossing fusion data set is built by combining ancient medical case text data related to traditional Chinese medicine heart failure; performing field fine tuning on the pre-training model to generate a basic teacher model; performing semantic alignment, and outputting a cross-time contrast database; constructing a curative effect scoring model by using the time sequence model, and outputting a quantitative association database; using a graph neural network to output an intelligent heart failure knowledge graph, and generating a comprehensive teacher model; performing knowledge distillation on the comprehensive teacher model to generate a clinical student model; the knowledge distillation system is applied to the knowledge distillation method, has a dynamic learning ability, can fuse ancient and modern trans-time knowledge and combine traditional Chinese medicine ancient book wisdom to carry out heart failure auxiliary diagnosis and treatment, and can give consideration to model performance and deployment efficiency through knowledge distillation.

The invention relates to application of tsRNA-3025a as a prognostic marker of acute myocardial infarction and a treatment target spot of myocardial ischemia reperfusion injury. A DNA (Deoxyribonucleic Acid) sequence corresponding to the tsRNA-3025a is shown as SEQ ID NO: 1: 5 '-ATCCTGCCGACTACGCCA-3'. The tsRNA-3025a can be used for treating acute myocardial infarction and myocardial ischemia reperfusion injury. In the aspect of prognosis, a detection kit is provided, and the risk of heart failure and short-term adverse events of a patient is evaluated by quantitatively detecting the expression level of the tsRNA. In the aspect of treatment, the invention provides the application of the anti-tagomir for inhibiting the function or expression of tsRNA-3025a in the preparation of the medicine for treating the myocardial ischemia reperfusion injury, and the anti-tagomir is subjected to specific chemical modification. A novel biomarker is provided for prognosis risk stratification of acute myocardial infarction, and an effective treatment strategy is provided for prevention and treatment of myocardial ischemia-reperfusion injury.

The invention discloses a cardiovascular risk early warning method based on multi-modal time sequence data, relates to the technical field of medical health information monitoring, and aims to solve the problem of confusion of causes of dyspnea at night by constructing a cross-modal direction and time delay relation in a sliding time window. Phenotype similar phenomena such as pure blood oxygen reduction / wake-up are decomposed into a comparable time sequence interaction structure, so that a blocking chain type process and a non-blocking type heart failure related process can be distinguished on the structural level, and therefore false alarm and missing alarm caused by confusion are reduced. Meanwhile, a multi-channel signal is firstly converted into a time sequence causal diagram, and then in-window statistical characteristics are combined for judgment, so that the model not only utilizes the self change of each channel, but also utilizes the interaction evidence of the first and second channels, the influence direction and the delay length, and the expression ability of the pathophysiological chain difference is improved.

Provided herein is a method of using digital twins for medical diagnosis, prediction, and / or prognosis of a disease or condition, such as diagnosis, prediction, and / or prognosis of one or more cancers, organ-specific age prediction, predicting of female aging, predicting hospital-acquired infection, predicting dialysis time series, predicting diabetes and complications, predicting pregnancy and child outcome, predicting heart failure, predicting myopia, predicting vision in anti-VEGF treatment, or any combination thereof. A system and non-transitory computer-readable storage medium configured for performing the method is also disclosed.

The invention relates to the technical field of physiological signal processing, and discloses a millimeter wave radar multi-dimensional physiological feature decoupling heart failure early warning system and method, and the method comprises the steps: configuring a millimeter wave radar to transmit a dual-beam frequency modulation continuous wave signal, collecting human body reflection echoes, and generating a multi-channel original digital signal matrix; generating a chest region and acra region phase signal, an overall reflection signal amplitude sequence and an overall phase drift signal after spatial isolation enhancement through distance-Doppler combined processing; decoupling to obtain a beat-by-beat heartbeat interval sequence, a pulse wave transmission time sequence and a daily net body fluid variation sequence; obtaining a rule engine risk level and a machine learning early warning sign, and determining a final risk assessment level through fusion decision; synchronous high-precision collection and decoupling of non-contact multi-dimensional physiological parameters are achieved, and accuracy and specificity of heart failure decompensation early warning are improved through double-layer model fusion.

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

The invention provides an application of a CGRP inhibitor in preparation of a medicine for treating myocardial infarction or heart failure, relates to the technical field of biomedicine, and has the technical key points that the invention provides the CGRP inhibitor Rimegepant and provides an effect of the CGRP inhibitor Rimegepant in myocardial infarction and heart failure, and the CGRP inhibitor Rimegepant can be used for preparing a medicine for treating myocardial infarction or heart failure. The myocardial infarction and / or heart failure model is constructed through left anterior descending branch coronary artery ligation. In-vitro experiments verify that the expression of the CGRP receptor protein in the heart of a mouse after heart failure is increased, and prove that the CGRP inhibitor Rimegeant can effectively inhibit the expression of the CGRP receptor protein, and further research is carried out, so that a potential treatment strategy is provided for drug research and development. The in-heart CGRP receptor inhibitor can obviously relieve the myocardial infarction and / or heart failure course of mice, and down-regulate the protein expression of the CGRP receptor at the same time.

The present disclosure relates treating skeletal muscle weakness associated with heart failure by administering a compound that binds to leaky ryanodine receptors (RyRs). Compounds of the present disclosure can bind to and repair the leak in both RyR1 and RyR2 to improve skeletal muscle and cardiac function, respectively.

The application discloses a fish scale protein polypeptide anti-chronic heart failure efficacy evaluation system, relates to the technical field of biological active polypeptide evaluation and cardiovascular disease function analysis, and comprises a raw material processing module for preparing fish scale protein polypeptides, a CHF model construction module for animal experiments, a function detection module, and a data processing and analysis module. Multidimensional statistics and visual algorithm are adopted to integrate tissue remodeling indexes such as heart function, oxidative stress and inflammatory reaction, so that comprehensive evaluation of the efficacy of fish scale protein polypeptides is realized. The application can realize systematic, quantitative and mechanistic evaluation of the anti-chronic heart failure effect of fish scale protein polypeptides, solve the problems of single evaluation index, poor repeatability of results and lack of mechanism correlation in the prior art, and has the advantages of comprehensive evaluation, reliable results, wide application range and strong generalizability.

The invention relates to the field of deep learning, and discloses a heart failure patient home care intelligent monitoring method combined with deep learning, which comprises the following steps: continuously acquiring the heart rate, blood pressure, breathing and body movement states of a patient in a home environment; performing conjoint analysis of time and activity states on the data streams after priority sorting, and forming a dynamic health feature set in combination with historical health records of patients and environment variable information; comprehensively evaluating the dynamic health feature set by using a deep learning model, and identifying a potential abnormal mode of short-time change through the deep learning model; marking and grouping the physiological parameters and related behavior scenes corresponding to the candidate abnormal events, locally evaluating the current health state of the patient based on grouping information, and identifying a potential high-risk condition; and according to the local evaluation result and the overall health trend of the patient, generating real-time early warning and personalized nursing suggestions. The method has the advantage of improving the identification capability of short-time abnormity.

The present invention provides, in part, a novel small molecule PHD inhibitor having a structure according to Formula (A) or a sub-formula thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein are useful in the treatment of diseases, including heart diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung diseases (e.g., acute lung injury, pulmonary arterial hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver diseases (e.g., acute liver failure and liver fibrosis, and cirrhosis), and kidney diseases (e.g., acute liver failure, liver fibrosis, and cirrhosis). Acute kidney injury and chronic kidney disease).

A lung sound analysis system includes a storage means for storing therein the history of auscultation observations on lung sound data of each of auscultation positions of a subject who is a heart failure patient, a calculation means for calculating appearance frequency of abnormal sounds for each of the auscultation positions on the basis of the history, a determination means for determining the sequence of the auscultation positions at which lung sounds are to be auscultated from the subject, on the basis of the calculated appearance frequency, and an acquisition means for giving guidance on the auscultation positions of the subject to an operator according to the determined sequence, and acquiring time-series acoustic signals including lung sounds from a guided auscultation position. The system supports medical decision-making for healthcare professionals monitoring heart failure patients.

The invention discloses a preparation method of yang-strengthening heart-strengthening decoction for improving the treatment efficacy of moderate and severe heart failure, and belongs to the field of traditional Chinese medicine preparation. The method aims at solving the problems that an existing traditional Chinese medicine prescription is not strict in safety control, unstable in quality and the like. The preparation method comprises the following steps: weighing the following medicinal materials in parts by weight: black prepared aconite root, ginseng and the like, and carrying out special pretreatment of soaking and decocting the monarch drug black prepared aconite root so as to remarkably reduce the toxicity of the black prepared aconite root; combining the pretreated black prepared common monkshood daughter root with other medicinal materials, decocting, and filtering to obtain an extracting solution; preparing the extracting solution into a dry extract by adopting a vacuum concentration and drying process and introducing key quality control indexes such as relative density and water content; and finally, preparing the dried extract into modern solid preparations such as granules or capsules and the like. According to the invention, through source toxicity reduction and process quantitative control, the safety of the product and the uniformity of batch-to-batch quality are ensured, meanwhile, the dosage form is optimized, and the convenience and compliance of medication of patients are improved. The invention further discloses a process flow diagram of the preparation method.

To provide a method of treating a patient with chronic heart failure using a medicament comprising neuregulin.SOLUTION: A companion diagnostic test is first performed on each patient prior to treatment, and the appropriate treatment is provided to each patient according to the companion diagnostic test results. If the test results are within a preferred therapeutic range for treatment, the patient is suitable for treatment of heart failure by administration of an effective amount of neuregulin.SELECTED DRAWING: None

A lung sound analysis system includes a storage means for storing therein the history of auscultation observations on lung sound data of each of auscultation positions of a subject who is a heart failure patient, a calculation means for calculating appearance frequency of abnormal sounds for each of the auscultation positions on the basis of the history, a determination means for determining the sequence of the auscultation positions at which lung sounds are to be auscultated from the subject, on the basis of the calculated appearance frequency, and an acquisition means for giving guidance on the auscultation positions of the subject to an operator according to the determined sequence, and acquiring time-series acoustic signals including lung sounds from a guided auscultation position. The system supports medical decision-making for healthcare professionals monitoring heart failure patients.

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

This invention relates to a method and system for cardiovascular disease risk assessment based on machine learning models. By utilizing machine learning models to focus on predicting the risk of heart failure, it accurately distinguishes between healthy individuals and those with cardiovascular disease, emphasizing the differentiation of heart failure and other common cardiovascular diseases, and deeply exploring diagnostic indicators, thus opening new avenues for cardiovascular diagnosis and treatment. It hierarchically utilizes features closely related to blood cells, blood lipids, and blood glucose, and constructs predictive models using multiple machine learning models, laying a solid foundation for further in-depth research. This invention fully utilizes diagnostic indicators and multiple machine learning models, making full use of the predictive results and differentiated characteristics of different machine learning models to achieve efficient and accurate 5-category risk assessment.

The invention relates to the technical field of biological medicines, in particular to application of a monoclonal antibody in medicines for treating heart diseases related to Alzheimer's disease. According to the application disclosed by the invention, the application range of the lencanamazumab is expanded to prevention and treatment of AD-accompanied heart failure and pathological myocardial remodeling, and a new drug strategy is provided for treatment of patients with AD-associated heart failure or pathological myocardial remodeling.

The invention relates to the technical field of traditional Chinese medicine preparations, in particular to an anti-heart-failure traditional Chinese medicine composition and a pharmaceutical preparation. The traditional Chinese medicine composition comprises sun-dried ginseng, radix ophiopogonis, schisandra chinensis, American ginseng, pseudo-ginseng and poria cocos. The traditional Chinese medicine composition for resisting heart failure and the medicinal preparation provided by the invention can relieve myocardial damage and load of patients with heart failure and relieve myocardial hypertrophy and fibrosis, so that the heart function of the patients with heart failure is effectively improved.

The present disclosure relates to a device assembly and a method for treating heart failure by normalizing elevated blood pressure in the left atrium of a heart of a mammal. Disclosed herein is a transcatheter interatrial septum excision device assembly configured to create a sized interatrial aperture between the right and left atria of a heart for the relief of elevated left atrial pressure. The device assembly comprises a delivery catheter, a tissue stabilizer attached to a first catheter having a central lumen and a penetrating tip that permits passage of a guidewire, and a cutter attached to a second catheter having a central lumen that permits passage of the first catheter. Alternative configurations comprise a (third) catheter having a central lumen that permits passage of the aforementioned components to and from the right atrium, a tissue retention mechanism and an optional coaxial alignment mechanism.

The utility model discloses a portable traditional Chinese medicine olfactory diagnosis instrument, which comprises a sample collection device, a gas enrichment device, a mass spectrometer, a data processor and a display, the mass spectrometer is sequentially connected with the data processor and the display, the gas enrichment device is test paper with an enrichment reagent encapsulating nano-metal particles, the enrichment efficiency is effectively improved, and the detection accuracy is improved. Therefore, the detection sensitivity and accuracy of the mass spectrometer are improved; the device is provided with the ion trap mass spectrometer, has the characteristics of high detection speed, high resolution and high sensitivity, and has performance advantages in qualitative and trace analysis aspects; and due to small volume and strong portability, the device can be conveniently integrated into portable or field detection equipment, can be used for auxiliary diagnosis of heart failure and asthma, and also has great clinical application value in the aspects of disease evolution and disease prognosis evaluation.

Disclosed herein are methods and compositions for the detection of biomarkers for cardiac diseases. Disclosed herein are sample collection devices comprising detection devices for heart failure. Disclosed herein are methods of detecting, monitoring, preventing, or treating heart failure.

A method of cardiac treatment to provides a synergetic therapeutic effect of lowering the hyperactive sympathetic response observed in microvascular disease (MVD) and heart failure (HF) pathologies and promoting cardiac remodeling of left ventricular hypertrophy in a patient. The method may include ablating renal sympathetic nerves of the patient to reduce sympathetic afferent and efferent activity to the kidney, thereby reducing blood pressure, delivering cardiac pacing to induce remodeling of hypertrophy of the left ventricle of the patient's heart, and stimulating a vagus nerve of the patient to induce an anti-inflammatory reflex in the patient's heart. The method may include ablating renal sympathetic nerves of the patient to reduce sympathetic afferent and efferent activity to the kidney, thereby reducing blood pressure, and stimulating carotid baroreceptors of the patient to downregulates sympathetic tone and upregulates parasympathetic tone.

A system for determining heart failure exacerbation includes a wearable device measuring biological data and motion data of a subject, and a server connectable to the wearable device to: acquire the biological data and motion data at each time point in a predetermined period; calculate a parameter related to a heart based on the biological data; calculate an activity amount based on the motion data; identify active time points where the calculated activity amounts are equal to or greater than a predetermined value; identify specific parameters at delayed time points when a predetermined time has elapsed from the active time points; and calculate an index value related to the heart failure exacerbation based on a relationship between the activity amounts at the active time points and the specific parameters at the delayed time points.

A new blood assay is provided which identifies patients who develop hemorrhage after revascularization therapy based on temporal kinetics of free serum iron levels. This approach overcomes the limitations of gold-standard clinical practice of performing cardiac magnetic resonance imaging, as the latter is not always accessible due to poor availability and a high cost. The blood assay can be a new diagnostic approach to broadly permit classification of myocardial infarction based on hemorrhage status, and to allow for suitable management of hemorrhagic patients, who would otherwise carry a significant risk for heart failure and sudden death.

The application discloses a traditional Chinese medicine composition for treating heart failure and a preparation method thereof, and relates to the field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from red ginseng, Coptis chinensis, trichosanthes peel, earthworm, Rhodiolae, Ganoderma lucidum spore powder, Radix Polygoni Multiflori, Prunella vulgaris, prepared licorice and cassia twig. The traditional Chinese medicinal materials are soaked and then decocted, the filtrate is collected, filtered, concentrated, and then the extract is obtained, and the Ganoderma lucidum spore powder is added to prepare the traditional Chinese medicine composition. The composition is prepared according to the compatibility principles of tonifying deficiency and reducing excess, and regulating cold and heat, and can accurately match the syndrome type of yangqi deficiency, phlegm-heat and blood stasis blocking and collateral damage and yin exhaustion, thereby significantly improving the ejection fraction preserved heart failure composite syndrome type of chronic heart failure.

The utility model relates to the technical field of heart failure rehabilitation training, in particular to a heart failure rehabilitation training device which comprises a base, an air blowing mechanism is connected to one side of the base, a training mechanism is detachably arranged at the upper end of the base, an air flow channel is formed in the middle of the interior of the base, and the heart failure rehabilitation training device further comprises a connecting mechanism arranged on the base. The training mechanism is detachably connected with the base through the connecting mechanism; the positioning mechanism is arranged at the upper end of the base, the training mechanism and the base are connected through the positioning mechanism and then are positioned, according to the heart failure rehabilitation training device, different numbers of inflators can be selected for breathing gas training according to the requirements of patients, and therefore the heart failure rehabilitation training device is suitable for the patients with different requirements.